Why Marvell's AI Revenue Could Top $4 Billion By 2025, Analyst Explains
JP Morgan analyst Harlan Sur maintained an Overweight rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a price forecast of $130 on Tuesday.
This price forecast is based on Marvell's strong market leadership in optical connectivity, synergies with its Storage, Networking, and embedded processing franchises, and its solid growth outlook in AI/Networking, Sur asserted.
Marvell will report earnings on Thursday, and Sur expects a continued volume ramp of Amazon.Com, Inc. (NASDAQ:AMZN) Trainium 2 ASIC and Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) Google Axion ARM CPU programs, strong demand for its 800G products, and the initial ramp of 1.6T optical DSPs, combined with a continued cyclical recovery in its enterprise and carrier segments.Overall, the analyst expects April quarter results ($1.875 billion, up 3% Q/Q) and July quarter guidance ($2.00 billion+, 7% Q/Q) to be in line with Sur and consensus estimates, with solid data center growth led by its AI ASIC ramps, growth in 800G/1.6T AI optical shipments, 400ZR shipments, and HDD/SSD controllers. He noted that the remainder of its business should drive a Q/Q growth profile on cyclical improvements/new product cycles.
Sur noted that Marvell's Microsoft Corp. (NASDAQ:MSFT) AI ASIC MAIA Gen 2-3nm program is on track to ramp in calendar year 2026. Marvell has also won the Gen 3 MAIA program and has already commenced early chip design activity, he stated.
The analyst said that 800G PAM4 optical DSP orders and shipments remain solid within Marvell's optical business, with an increasing ramp of next-gen 1.6T DSP into the second half.
Sur noted that Marvell is tracking to drive $4 billion in AI revenues this year (ASICs + networking), up 2x+ Y/Y, with a strong growth profile into calendar year 2026.
In cyclical business, demand from enterprise networking (Cisco Systems, Inc. (NASDAQ: CSCO)) remains healthy, and demand for carrier infrastructure is stabilizing, as per Sur.
In automotive, the divestiture of the auto business, expected to close in the calendar year 2025 ($225-$250 million revenue in the fiscal year 2026), is a revenue headwind but should be overall accretive to the Marvell's earnings power by $0.05-$0.10, the analyst said. More importantly, he noted the custom data center and AI ASIC pipeline are continuing to expand.
Price Action: MRVL stock was trading higher by 5.69% to $64.15 at last check Tuesday.
Read Next:Photo by JHVEPhoto via Shutterstock
Date
Firm
Action
From
To
Mar 2022
Susquehanna
Maintains
Positive
Mar 2022
Summit Insights Group
Downgrades
Buy
Hold
Mar 2022
Morgan Stanley
Maintains
Equal-Weight
View More Analyst Ratings for MRVL
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
MARVELL TECH (MRVL): Free Stock Analysis Report
This article Why Marvell's AI Revenue Could Top $4 Billion By 2025, Analyst Explains originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NVIDIA (NasdaqGS:NVDA) Collaborates With Accenture And AdaCore For AI And Automotive Innovation
NVIDIA has gained attention with its recent expansion in AI startups and introduction of new programming languages for the automotive market, coinciding with a 28% share price increase in the last quarter. These developments align with the broader market's modest upward trend, as the S&P 500 and Nasdaq both marked winning streaks, lifted by renewed economic optimism and progress in trade talks with China. NVIDIA's collaboration with Accenture, AdaCore, and various industry leaders adds weight to its momentum, complementing its focus on AI and autonomous technology, which have remained key drivers of interest amid robust market conditions. We've spotted 1 possible red flag for NVIDIA you should be aware of. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent developments at NVIDIA, particularly its expansion into AI startups and new programming languages for the automotive market, could significantly influence its long-term growth narrative. The partnerships with industry giants Toyota and Uber aim to cement NVIDIA's presence in the autonomous vehicles sector, potentially boosting revenue streams and market share. These collaborations align with NVIDIA's focus on AI and autonomous technology, potentially enhancing its data center and AI workloads, which in turn might improve earnings and margin potential. Analysts have projected NVIDIA's earnings to grow substantially, assuming it capitalizes on these burgeoning opportunities. However, regulatory challenges and export controls could impact these forecasts, as uncertainty remains a persistent risk. Over the past five years, NVIDIA's total return, including share price appreciation and dividends, has been very large, reflecting significant long-term value creation. In comparison to its one-year performance, NVIDIA surpassed the US Semiconductor industry, which posted a 10.3% gain, suggesting strong relative performance. This longer-term gain is a testament to NVIDIA's rapid growth trajectory, bolstered by innovation and strategic sector expansions. Despite the impressive gains, NVIDIA's current share price of US$113.54 is significantly lower than the consensus analyst price target of US$163.12, indicating potential room for growth. As the company continues to navigate AI and automotive sectors, these market moves can be pivotal in driving future revenue and earnings. Investors may need to assess if the growth potential justifies the price target, considering the associated risks and market dynamics. The ongoing scaling of the Blackwell architecture and its implications for operational efficiency and cost management will be central to NVIDIA meeting or exceeding analyst expectations. Assess NVIDIA's future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:NVDA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Is It Time to Buy Peloton Stock? Here's the Good News and the Bad News.
Peloton Interactive's stock price has plunged by 95% from its 2021 high. The company continues to grapple with shrinking sales, but it's making progress at the bottom line. A beaten-down stock doesn't always equal a cheap stock, and that might be the case here. 10 stocks we like better than Peloton Interactive › Peloton Interactive (NASDAQ: PTON) stock peaked at $163 in 2021, which represented an eye-popping return of 460% for investors who bought it at the time of its initial public offering (IPO) the year before. But the stock has since lost 95% of its peak value, and a recovery appears uncertain. Consumers were buying at-home exercise equipment hand over fist at the height of the COVID-19 pandemic, so they could stay fit during the lockdowns and social restrictions. But Peloton failed to evolve once that demand cooled off, which sent its revenue plunging and its losses soaring. There was even a period of time when Peloton's survival was in question, before management made a series of changes. The company's future is still uncertain, but there is now some good news to go along with its ongoing struggles. Here's what investors need to know before deciding whether to buy the stock. Peloton generates revenue in two ways. First, it sells exercise equipment like its stationary bikes, treadmills, and rowing machines. Second, it offers a subscription product for customers who want to access exclusive classes to get the most out of their Peloton equipment, and also a separate subscription product for non-equipment owners who want to track their fitness journeys. Peloton's annual revenue peaked at $4 billion during its fiscal year 2021 (ended June 30, 2021), and it has declined every year since. It fell to $3.5 billion in fiscal 2022, then $2.8 billion in fiscal 2023, and $2.7 billion in fiscal 2024. Management's fiscal 2025 forecast suggests it will decline even further in the current year, to just under $2.5 billion. The composition of Peloton's revenue has changed dramatically over the last few years. In fiscal 2021, equipment sales represented 78% of the company's total revenue, with subscriptions accounting for the other 22%. But equipment sales now make up just 33% of total revenue, with subscriptions representing the majority. Demand has declined dramatically for Peloton's flagship exercise machines since the height of the pandemic. The company has pulled several different levers to resurrect it, but they don't appear to be working. It closed many of its stores and shifted sales to third-party retailers like Amazon and Dick's Sporting Goods to reach more customers, and it even launched financing and rental options to reduce the entry cost for lower-income consumers. Connected fitness subscriptions are directly tied to equipment sales, so if Peloton sells fewer bikes, treadmills, and rowing machines, it also becomes harder to grow its subscriber base. In fact, it shrank by 6% over the past year, to 2.88 million members. Shrinking businesses can destroy shareholder value over time, so investors typically avoid buying into them (hence the 95% drop in Peloton's share price over the last few years). In fiscal 2022 -- the first year Peloton's revenue declined -- management still had its cost structure geared toward growth. In other words, it was spending more money with less money coming in. As a result, the company wound up generating a staggering generally accepted accounting principles (GAAP) net loss of $2.8 billion that year. That was completely unsustainable, and Peloton faced the possibility of bankruptcy if it couldn't reduce its losses because its cash balance was quickly evaporating. Since then, management has slashed costs and secured financing to protect Peloton's future. In fiscal 2024, the company's operating expenses were down by almost half compared to their fiscal 2022 level, led by cuts to sales and marketing. The downtrend continued in the first three quarters of fiscal 2025, with operating expenses cut by a further 26% year over year. Peloton is still in the red on a GAAP basis, generating a net loss of $140 million in fiscal 2025 to date. However, after stripping out one-off and non-cash expenses like stock-based compensation, the company has actually generated positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $70.3 million during the period. This is management's preferred measure of profitability, because it's a better indicator of how much real money the business is generating. This is good news in the sense that Peloton is no longer at risk of going out of business in the near future. But there is no telling where the bottom is in terms of the company's shrinking revenue. Management will eventually run out of costs to cut, which could put the business in a precarious position yet again at some point. Peloton has $914 million in cash on its balance sheet, and now that it's profitable (on a non-GAAP EBITDA basis), it has an opportunity to start investing in growth again. However, it also has $947 million in long-term debt, so it can't get too adventurous and start burning cash at the bottom line. Earlier, I said investors typically avoid buying into shrinking businesses. If Peloton can't find a way to reignite its sales growth in a sustainable way, then it's probably going to face mounting losses again in the future. That creates a significant risk for investors who buy the stock today, even though it's already down by 95% from its record high. This is one of those situations where a beaten-down stock doesn't necessarily equal a cheap stock, so investors might want to stay away until Peloton proves it can sustainably grow its sales. Before you buy stock in Peloton Interactive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Peloton Interactive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Peloton Interactive. The Motley Fool has a disclosure policy. Is It Time to Buy Peloton Stock? Here's the Good News and the Bad News. was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial. The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc's (NASDAQ:REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 treatment has been generally well-tolerated to date in this heavily pretreated population. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months. 'This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,' said MAIA Chairman and CEO Vlad Vitoc. MAIA's multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of at least 30%. 'The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,' Vitoc added. Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
